Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.74 |
| ▸ | TYMS | P04818 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605275 | 0.85 | DHFR (0.74) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL3607641 | 0.81 | DHFR (1.00) | DHFRTYMSMEN1LMNAMAPT | |
| SCHEMBL649476 | 0.72 | DHFR (0.67) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL4635984 | 0.69 | DHFR (0.59) | DHFRTYMSMEN1LMNAMAPT | |
| SCHEMBL16283360 | 0.68 | LMNA (0.61) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL11443116 | 0.64 | TYMS (0.58) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL3654713 | 0.62 | LMNA (0.76) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL30669861 | 0.62 | LMNA (0.76) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL16283365 | 0.62 | LMNA (0.61) | DHFRTYMSMEN1LMNAPOLB | |
| SCHEMBL29027 | 0.62 | PTPN22 (0.65) | MEN1POLBMAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048692-A1 | Naphthofuranone Derivatives as Specific Inhibitors of Thymidylate Synthases | TYDOCKPHARMA S.R.L. (IT) | 2010-02-25 | — | — | US | claimed |
| EP-2044047-A1 | NAPHTHOFURANONE DERIVATIVES AS SPECIFIC INHIBITORS OF THYMIDYLATE SYNTHASES | TydockPharma S.r.l. (IT) | 2009-04-08 | — | — | EP | claimed |
| WO-2008003510-A1 | NAPHTHOFURANONE DERIVATIVES AS SPECIFIC INHIBITORS OF THYMIDYLATE SYNTHASES | TYDOCKPHARMA S.R.L. (IT) | 2008-01-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048692-A1 | Naphthofuranone Derivatives as Specific Inhibitors of Thymidylate Synthases | TYMS, TYMP, DNTT | DHFR 12/4885TYMS 1/4885MEN1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.